Therapeutically Significant MicroRNAs in Primary and Metastatic Brain Malignancies

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Sep 10

PMID 32906592

Citations 16

Authors

Akilandeswari A Balachandran

Leon M Larcher

Suxiang Chen

Rakesh N Veedu

Affiliations

Soon will be listed here.

Abstract

Brain cancer is one among the rare cancers with high mortality rate that affects both children and adults. The most aggressive form of primary brain tumor is glioblastoma. Secondary brain tumors most commonly metastasize from primary cancers of lung, breast, or melanoma. The five-year survival of primary and secondary brain tumors is 34% and 2.4%, respectively. Owing to poor prognosis, tumor heterogeneity, increased tumor relapse, and resistance to therapies, brain cancers have high mortality and poor survival rates compared to other cancers. Early diagnosis, effective targeted treatments, and improved prognosis have the potential to increase the survival rate of patients with primary and secondary brain malignancies. MicroRNAs (miRNAs) are short noncoding RNAs of approximately 18-22 nucleotides that play a significant role in the regulation of multiple genes. With growing interest in the development of miRNA-based therapeutics, it is crucial to understand the differential role of these miRNAs in the given cancer scenario. This review focuses on the differential expression of ten miRNAs (miR-145, miR-31, miR-451, miR-19a, miR-143, miR-125b, miR-328, miR-210, miR-146a, and miR-126) in glioblastoma and brain metastasis. These miRNAs are highly dysregulated in both primary and metastatic brain tumors, which necessitates a better understanding of their role in these cancers. In the context of the tumor microenvironment and the expression of different genes, these miRNAs possess both oncogenic and/or tumor-suppressive roles within the same cancer.

Citing Articles

miR-210 loss leads to widespread phenotypic and gene expression changes in human 293T cells.

Zhang X, Meng Z, Yang C, Wang C, Zhang K, Shi A Front Genet. 2024; 15:1486252.

PMID: 39737000 PMC: 11683127. DOI: 10.3389/fgene.2024.1486252.

Breast cancer cell-secreted miR-199b-5p hijacks neurometabolic coupling to promote brain metastasis.

Ruan X, Yan W, Cao M, Daza R, Fong M, Yang K Nat Commun. 2024; 15(1):4549.

PMID: 38811525 PMC: 11137082. DOI: 10.1038/s41467-024-48740-0.

Neutrophil extracellular traps in central nervous system (CNS) diseases.

Shao B, Jiang J, Zhao Y, Zheng X, Xi N, Zhao G PeerJ. 2024; 12:e16465.

PMID: 38188146 PMC: 10771765. DOI: 10.7717/peerj.16465.

Nikolova E, Laleva L, Milev M, Spiriev T, Stoyanov S, Ferdinandov D Noncoding RNA Res. 2023; 9(1):141-152.

PMID: 38035044 PMC: 10686814. DOI: 10.1016/j.ncrna.2023.10.003.

Insights into the Role of LncRNAs and miRNAs in Glioma Progression and Their Potential as Novel Therapeutic Targets.

Kciuk M, Yahya E, Mohamed M, Abdulsamad M, Allaq A, Gielecinska A Cancers (Basel). 2023; 15(13).

PMID: 37444408 PMC: 10340789. DOI: 10.3390/cancers15133298.

References

Zhou R, Xu X, Liu B, Dai W, Cai M, Bai C . Growth-inhibitory and chemosensitizing effects of microRNA-31 in human glioblastoma multiforme cells. Int J Mol Med. 2015; 36(4):1159-64. DOI: 10.3892/ijmm.2015.2312. View

Wong H, El Fatimy R, Onodera C, Wei Z, Yi M, Mohan A . The Cancer Genome Atlas Analysis Predicts MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma. Mol Ther. 2015; 23(7):1234-1247. PMC: 4817797. DOI: 10.1038/mt.2015.72. View

Qin N, Tong G, Sun L, Xu X . Long Noncoding RNA MEG3 Suppresses Glioma Cell Proliferation, Migration, and Invasion by Acting as a Competing Endogenous RNA of miR-19a. Oncol Res. 2017; 25(9):1471-1478. PMC: 7841124. DOI: 10.3727/096504017X14886689179993. View

Luan Y, Zuo L, Zhang S, Wang G, Peng T . MicroRNA-126 acts as a tumor suppressor in glioma cells by targeting insulin receptor substrate 1 (IRS-1). Int J Clin Exp Pathol. 2015; 8(9):10345-54. PMC: 4637557. View

Wang L, Shi Z, Jiang C, Liu X, Chen Q, Qian X . MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma. Oncotarget. 2014; 5(14):5416-27. PMC: 4170647. DOI: 10.18632/oncotarget.2116. View

Borchert G, Lanier W, Davidson B . RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol. 2006; 13(12):1097-101. DOI: 10.1038/nsmb1167. View

Krek A, Grun D, Poy M, Wolf R, Rosenberg L, Epstein E . Combinatorial microRNA target predictions. Nat Genet. 2005; 37(5):495-500. DOI: 10.1038/ng1536. View

Yang J, Lai E . Alternative miRNA biogenesis pathways and the interpretation of core miRNA pathway mutants. Mol Cell. 2011; 43(6):892-903. PMC: 3176435. DOI: 10.1016/j.molcel.2011.07.024. View

Chen W, Lang Z, Ren C, Yang P, Zhang B . miR‑143 acts as a novel Big mitogen‑activated protein kinase 1 suppressor and may inhibit invasion of glioma. Oncol Rep. 2019; 42(3):1194-1204. DOI: 10.3892/or.2019.7218. View

10.

Skog J, Wurdinger T, van Rijn S, Meijer D, Gainche L, Sena-Esteves M . Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10(12):1470-6. PMC: 3423894. DOI: 10.1038/ncb1800. View

11.

Rajbhandari R, McFarland B, Patel A, Gerigk M, Gray G, Fehling S . Loss of tumor suppressive microRNA-31 enhances TRADD/NF-κB signaling in glioblastoma. Oncotarget. 2015; 6(19):17805-16. PMC: 4627347. DOI: 10.18632/oncotarget.4596. View

12.

Zhao H, Shen J, Hodges T, Song R, Fuller G, Heimberger A . Serum microRNA profiling in patients with glioblastoma: a survival analysis. Mol Cancer. 2017; 16(1):59. PMC: 5346242. DOI: 10.1186/s12943-017-0628-5. View

13.

Crawford M, Brawner E, Batte K, Yu L, Hunter M, Otterson G . MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun. 2008; 373(4):607-12. DOI: 10.1016/j.bbrc.2008.06.090. View

14.

Shah V, Kochar P . Brain Cancer: Implication to Disease, Therapeutic Strategies and Tumor Targeted Drug Delivery Approaches. Recent Pat Anticancer Drug Discov. 2017; 13(1):70-85. DOI: 10.2174/1574892812666171129142023. View

15.

Li X, Zheng J, Chen L, Diao H, Liu Y . Predictive and Prognostic Roles of Abnormal Expression of Tissue miR-125b, miR-221, and miR-222 in Glioma. Mol Neurobiol. 2014; 53(1):577-583. DOI: 10.1007/s12035-014-9017-x. View

16.

Nan Y, Han L, Zhang A, Wang G, Jia Z, Yang Y . MiRNA-451 plays a role as tumor suppressor in human glioma cells. Brain Res. 2010; 1359:14-21. DOI: 10.1016/j.brainres.2010.08.074. View

17.

Shi L, Zhang S, Feng K, Wu F, Wan Y, Wang Z . MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int J Oncol. 2011; 40(1):119-29. DOI: 10.3892/ijo.2011.1179. View

18.

Bronisz A, Godlewski J, Chiocca E . Extracellular Vesicles and MicroRNAs: Their Role in Tumorigenicity and Therapy for Brain Tumors. Cell Mol Neurobiol. 2016; 36(3):361-76. PMC: 5570546. DOI: 10.1007/s10571-015-0293-4. View

19.

Baffa R, Fassan M, Volinia S, OHara B, Liu C, Palazzo J . MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol. 2009; 219(2):214-21. DOI: 10.1002/path.2586. View

20.

Van Rooij E, Kauppinen S . Development of microRNA therapeutics is coming of age. EMBO Mol Med. 2014; 6(7):851-64. PMC: 4119351. DOI: 10.15252/emmm.201100899. View